Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Aarti Drugs Ltd

AARTIDRUGS.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Small Cap Analyst: HOLD

Last Close

$4.57

▲ +1.36%

Market Cap $416.96M · Vol 250.31K

Key Metrics

P/E Ratio

20.62

FWD: 16.95

Market Cap

$416.96M

Small Cap

Div Yield

0.46%

Semi-annual dividend

EPS Growth

+29.19%

YoY

RSI (14)

64.82

Momentum

Beta

1.04

vs Market

52W High

$5.66

24.71% below

52W Low

$3.38

35.15% above

Volume

250.31K

Avg 203.83K

P/B

N/A

Price-to-book

ROE

13.40%

Return on equity

Free Float

40.44%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Aarti Drugs Ltd (AARTIDRUGS.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AARTIDRUGS.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.13%

+4.25%

+15.15%

+19.75%

YTD

+4.86%

-9.00%

-38.14%

-30.52%

Financials & Valuation

TTM · Annual

Total Revenue	$274.49M
Net Income	$20.86M
Revenue Growth (YoY)	+19.01%
Gross Margin	34.29%
Operating Margin	N/A
Net Profit Margin	N/A
ROE	13.40%
ROA · ROIC	7.83% · N/A

P/E Ratio	20.62
Forward P/E (FY1)	16.95
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+29.19%
Outstanding Shares	91.27M

Technical Indicators

50-Day SMA	$4.34
200-Day SMA	$4.11
RSI (14)	64.82
Beta	1.04
52-Week High	$5.66
52-Week Low	$3.38

Volume Today	250.31K
Avg Daily Volume (30D)	203.83K
Relative Volume	1.23x
Volatility (10D)	26.10
Volatility (30D)	27.33
Free Float	40.44%

Analyst Consensus

HOLD

Current Price $4.57

Mean Target $4.97

52W Low$3.38 52W High$5.66

Current

Target

$3.38 $5.66

Current Analyst target

+8.83% upside potential · 1 analysts

Identifiers

ExchangeNSE India

FIGIBBG001S82NR7

ISININE767A01016

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 5, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Co -0.88% JNJ Johnson & Johnson -1.15% ABBV Abbvie Inc -1.44% NVS Novartis AG -1.90% NOVN.S Novartis AG -1.33%

Company Profile

Aarti Drugs Limited is an India-based company, which is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates in the pharmaceuticals segment. Its geographical segments include Out of India and India. The Company's APIs products include iprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole, ofloxacin, and others. Its specialty chemicals include benzene sulphonyl chloride, methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include alpha lipoic acid, itraconazole, ticagrelor, and sitagliptin. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SPA.